Barclays’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $870K | Hold |
40,000
| – | – | ﹤0.01% | 2832 |
|
|
2025
Q4 | $861K | Sell |
40,000
-30,000
| -43% | -$632K | ﹤0.01% | 3542 |
|
|
2025
Q3 | $1.35M | Buy |
70,000
+30,000
| +75% | +$535K | ﹤0.01% | 3187 |
|
|
2025
Q2 | $684K | Buy |
40,000
+15,000
| +60% | +$640K | ﹤0.01% | 3576 |
|
|
2025
Q1 | $1.6M | Buy |
25,000
+20,000
| +400% | +$2.11M | ﹤0.01% | 2802 |
|
|
2024
Q4 | $608K | Hold |
5,000
| – | – | ﹤0.01% | 3701 |
|
|
2024
Q3 | $624K | Buy |
+5,000
| New | +$691K | ﹤0.01% | 3638 |
|
|
2024
Q2 | – | Sell |
-5,000
| Closed | -$647K | – | 5274 |
|
|
2024
Q1 | $647K | Buy |
+5,000
| New | +$612K | ﹤0.01% | 3433 |
|
|
2022
Q1 | – | Sell |
-5,800
| Closed | -$522K | – | 5561 |
|
|
2021
Q4 | $522K | Hold |
5,800
| – | – | ﹤0.01% | 3186 |
|
|
2021
Q3 | $536K | Buy |
+5,800
| New | +$447K | ﹤0.01% | 3154 |
|
|
2021
Q1 | – | Sell |
-8,000
| Closed | -$1.36M | – | 5153 |
|
|
2020
Q4 | $1.36M | Hold |
8,000
| – | – | ﹤0.01% | 2543 |
|
|
2020
Q3 | $1.12M | Sell |
8,000
-24,000
| -75% | -$3.65M | ﹤0.01% | 2593 |
|
|
2020
Q2 | $5.13M | Sell |
32,000
-106,500
| -77% | -$14.5M | ﹤0.01% | 1362 |
|
|
2020
Q1 | $13.5M | Sell |
138,500
-3,400
| -2% | -$389K | 0.01% | 835 |
|
|
2019
Q4 | $18.3M | Buy |
141,900
+47,200
| +50% | +$4.76M | 0.01% | 1001 |
|
|
2019
Q3 | $7.13M | Sell |
94,700
-71,200
| -43% | -$8.41M | ﹤0.01% | 1571 |
|
|
2019
Q2 | $25.2M | Sell |
165,900
-4,400
| -3% | -$535K | 0.02% | 804 |
|
|
2019
Q1 | $20.3M | Buy |
170,300
+116,000
| +214% | +$14.9M | 0.01% | 847 |
|
|
2018
Q4 | $5.93M | Buy |
54,300
+19,900
| +58% | +$2.49M | ﹤0.01% | 1485 |
|
|
2018
Q3 | $5.56M | Sell |
34,400
-58,300
| -63% | -$7.97M | ﹤0.01% | 1703 |
|
|
2018
Q2 | $12.3M | Buy |
92,700
+60,100
| +184% | +$5.67M | 0.01% | 1092 |
|
|
2018
Q1 | $2.42M | Sell |
32,600
-184,700
| -85% | -$12.3M | ﹤0.01% | 2289 |
|
|
2017
Q4 | $12.1M | Buy |
217,300
+118,600
| +120% | +$6.28M | 0.01% | 1083 |
|
|
2017
Q3 | $4.48M | Buy |
98,700
+13,900
| +16% | +$556K | ﹤0.01% | 1621 |
|
|
2017
Q2 | $2.86M | Buy |
84,800
+69,100
| +440% | +$2.25M | ﹤0.01% | 1937 |
|
|
2017
Q1 | $465K | Sell |
15,700
-176,200
| -92% | -$5.45M | ﹤0.01% | 3468 |
|
|
2016
Q4 | $5.26M | Sell |
191,900
-548,100
| -74% | -$22M | 0.01% | 1354 |
|
|
2016
Q3 | $45.4M | Buy |
740,000
+364,100
| +97% | +$11M | 0.05% | 274 |
|
|
2016
Q2 | $7.17M | Buy |
+375,900
| New | +$6.96M | 0.01% | 1054 |
|
|
2016
Q1 | – | Sell |
-88,200
| Closed | -$3.35M | – | 6417 |
|
|
2015
Q4 | $3.35M | Sell |
88,200
-93,400
| -51% | -$3.03M | ﹤0.01% | 1607 |
|
|
2015
Q3 | $5.81M | Buy |
181,600
+114,600
| +171% | +$3.89M | 0.01% | 1267 |
|
|
2015
Q2 | $2.01M | Buy |
+67,000
| New | +$1.37M | ﹤0.01% | 2218 |
|
|
2014
Q2 | – | Sell |
-24,000
| Closed | -$576K | – | 7795 |
|
|
2014
Q1 | $576K | Sell |
24,000
-271,000
| -92% | -$6.91M | ﹤0.01% | 3814 |
|
|
2013
Q4 | $5.9M | Sell |
295,000
-320,000
| -52% | -$9.51M | 0.01% | 1683 |
|
|
2013
Q3 | $28.9M | Sell |
615,000
-1,098,500
| -64% | -$42.3M | 0.03% | 497 |
|
|
2013
Q2 | $65.2M | Buy |
+1,713,500
| New | +$61.3M | 0.08% | 196 |
|
Other funds holding SRPT
VPM
VCM
RCM
EAM
Barclays's SRPT Position: Q1 2026 in Review
Barclays reduced its Sarepta Therapeutics (SRPT) stake by 42% in Q1 2026, selling an estimated $1.88M and leaving 135,959 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2125.
Barclays first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $63.3M in Q2 2024. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.
- Barclays held 135,959 shares of Sarepta Therapeutics worth $2.96M as of Q1 2026.
- Barclays sold 97,190 Sarepta Therapeutics shares in Q1 2026, an estimated $1.88M.
- Sarepta Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2125 holding.
- Barclays first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
- Barclays's Sarepta Therapeutics position peaked at $63.3M in Q2 2024.
- 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.